The Management of Chronic Coronary Arterial Disease and Related Comorbidities

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: closed (31 March 2022) | Viewed by 1806

Special Issue Editor


E-Mail Website
Guest Editor
Former Full Professor of Cardiovascular Diseases, University of Bologna, Bologna, Italy
Interests: internal medicine; cardiology; angiology; hematology

Special Issue Information

Dear Colleagues,

The issue of chronic coronary artery disease is always clear. These patients are at the intersection between clinical needs, the “offer” of technological advances, and the burden of concomitant illnesses. What are the patient expectations? What is the clinical yield of new technologies? When is revascularization worthwhile? To what extent should the patient in front of us enter a trial population? How can we take them to a lesser degree of anxiety, after having explained the full picture and put it in the right framework? How can we manage co-morbidities and related treatments? Should those treatments be pursued freely, or are there particular aspects to be considered? These are some of the main items facing physicians who take care of patients with chronic coronary artery disease. We believe that it is often difficult to choose the best pattern for every patient. A review of this subject should therefore be of interest to most readers.

Prof. Dr. Sergio Coccheri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • stable coronary disease
  • revascularization
  • non-invasive evaluation
  • imaging coronary arteries
  • co-morbidities

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 830 KiB  
Article
Plasma Concentrations of Cytokines in Patients with Combined Hyperlipidemia and Atherosclerotic Plaque before Treatment Initiation—A Pilot Study
by Marcin Basiak, Michal Kosowski, Marcin Hachula and Boguslaw Okopien
Medicina 2022, 58(5), 624; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina58050624 - 29 Apr 2022
Cited by 6 | Viewed by 1492
Abstract
Background and Objectives: The formation and destabilization of atherosclerotic plaques is a complex process involving several proteins and cytokines. Interleukin 6 (IL-6), interleukin 18 (IL-18), and tumor necrosis factor (TNF-α) are examples of such cytokines. The goal of our research is to [...] Read more.
Background and Objectives: The formation and destabilization of atherosclerotic plaques is a complex process involving several proteins and cytokines. Interleukin 6 (IL-6), interleukin 18 (IL-18), and tumor necrosis factor (TNF-α) are examples of such cytokines. The goal of our research is to compare the concentrations of the above-mentioned indicators in the plasma of patients with verified high-risk atherosclerotic plaque to the plasma levels of healthy people before lipid lowering therapy. Materials and Methods: Patients with dyslipidemia who had the presence of unstable atherosclerotic plaque verified by ultrasonography were included in the study. The concentrations of IL-6, IL-18 and TNF-α in the plasma of these people were determined and compared with the concentrations of these cytokines in the plasma of the control group. Results: Levels of lipid panel, IL-6 and IL-18 were significantly lower in the group of healthy people than in the study group. Conclusions: The concentrations of IL-6 and IL-18 in the plasma of patients with ruptured plaque are higher than in the plasma of healthy people, suggesting that these cytokines as a panel might be used as new indicators of the presence of unstable atherosclerotic plaque. Full article
Show Figures

Figure 1

Back to TopTop